The use of deucrictibant as potentially the first orally administered bradykinin B2 receptor antagonist for the treatment of attacks of bradykinin-mediated angioedema, including hereditary angioedema, is supported and may address an unmet need for options that are effective and well tolerated, with convenient administr...
M. Riedl, P. Li, A. Adatia et al.· The Lancet· 1 citation
ABSTRACT Introduction Hereditary Angioedema (HAE) is a rare disease affecting approximately 1 in 50,000 people. It results in angioedema of the skin, abdominal tract and upper airway that results in disfiguration, abdominal pain and potential for asphyxia. Early therapies for HAE have significant drug burden due to int...
Van Bui, Shane Stone, Bharosha Bhattarai et al.· Expert Opinion on Pharmacoth...· 0 citations
Lonvo-z uses CRISPR/Cas9 technology to permanently reduce production of prekallikrein that triggers swelling attacks in HAE, potentially providing long-lasting disease control after a single treatment.
L. Luong, Shane Stone, Van Bui et al.· Expert Opinion on Investigat...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.